Heron Therapeutics’ (HRTX) “Buy” Rating Reiterated at HC Wainwright

Heron Therapeutics (NASDAQ:HRTX)‘s stock had its “buy” rating reissued by investment analysts at HC Wainwright in a research report issued on Friday,Benzinga reports. They presently have a $6.00 price objective on the biotechnology company’s stock. HC Wainwright’s price target would indicate a potential upside of 301.34% from the company’s previous close.

HRTX has been the subject of a number of other reports. Jefferies Financial Group reaffirmed a “buy” rating on shares of Heron Therapeutics in a report on Tuesday, November 4th. Zacks Research upgraded Heron Therapeutics from a “strong sell” rating to a “hold” rating in a research report on Tuesday, October 7th. Finally, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Heron Therapeutics in a research report on Wednesday, October 8th. Three analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, Heron Therapeutics presently has an average rating of “Hold” and an average target price of $4.50.

Heron Therapeutics Stock Performance

NASDAQ HRTX traded up $0.23 on Friday, reaching $1.50. The stock had a trading volume of 3,432,593 shares, compared to its average volume of 1,860,248. The stock has a market cap of $274.12 million, a P/E ratio of -16.56 and a beta of 1.28. Heron Therapeutics has a 12-month low of $1.00 and a 12-month high of $2.68. The business’s 50-day moving average price is $1.22 and its 200 day moving average price is $1.43. The company has a debt-to-equity ratio of 19.89, a quick ratio of 1.78 and a current ratio of 2.56.

Heron Therapeutics (NASDAQ:HRTX) last announced its earnings results on Tuesday, November 4th. The biotechnology company reported ($0.05) EPS for the quarter, missing analysts’ consensus estimates of ($0.02) by ($0.03). The firm had revenue of $38.21 million for the quarter, compared to analyst estimates of $39.03 million. As a group, equities analysts expect that Heron Therapeutics will post -0.13 earnings per share for the current year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of HRTX. Goldman Sachs Group Inc. grew its position in shares of Heron Therapeutics by 57.0% in the first quarter. Goldman Sachs Group Inc. now owns 1,028,678 shares of the biotechnology company’s stock valued at $2,263,000 after purchasing an additional 373,518 shares during the last quarter. Congress Park Capital LLC grew its holdings in Heron Therapeutics by 11.4% during the 2nd quarter. Congress Park Capital LLC now owns 2,268,249 shares of the biotechnology company’s stock valued at $4,695,000 after buying an additional 232,632 shares during the last quarter. Palumbo Wealth Management LLC grew its holdings in Heron Therapeutics by 6.7% during the 2nd quarter. Palumbo Wealth Management LLC now owns 132,433 shares of the biotechnology company’s stock valued at $274,000 after buying an additional 8,330 shares during the last quarter. Cyndeo Wealth Partners LLC purchased a new position in Heron Therapeutics during the second quarter worth $514,000. Finally, AIGH Capital Management LLC raised its holdings in shares of Heron Therapeutics by 8.3% in the second quarter. AIGH Capital Management LLC now owns 3,009,257 shares of the biotechnology company’s stock worth $6,229,000 after acquiring an additional 231,057 shares during the last quarter. Institutional investors and hedge funds own 80.01% of the company’s stock.

Heron Therapeutics Company Profile

Heron Therapeutics, Inc is a commercial-stage biotechnology company focused on developing and commercializing therapies in pain management and supportive care for patients undergoing medical and surgical procedures. The company’s research is dedicated to addressing unmet needs in oncology supportive care and post-operative pain management through innovative drug formulations designed to improve patient outcomes and reduce reliance on opioids.

Heron’s first approved therapy, SUSTOL (granisetron) extended-release injection, received U.S.